BioCentury on BioBusiness,
Investors penalize Elan for restructured Tysabri deal with Biogen Idec
Related tables, figures and sidebars
Rethinking Elan, again
Monday, February 11, 2013
With a $3.3 billion windfall, Elan
Corp. plc (NYSE:ELN) has said it plans to shop for new assets and give some
money back to shareholders over time. Investors seem less than enthused,
however, and sent the shares down $1.06 to $9.40 on Wednesday after the biotech
agreed to restructure a 2000 deal for multiple sclerosis drug Tysabri
natalizumab with Biogen Idec Inc. (NASDAQ:BIIB).
It's possible that Elan shareholders
with long memories are having a sense of déjà vu. The company has restructured,
sought alternatives and/or sold off chunks of its business almost a dozen times
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]